 | | Vol. 13.21 – 3 June, 2021 |
| |
|
|
| Researchers demonstrated that inflammatory mediators, including IFNγ and polyIC, potentiated the cytotoxicity of phenformin by inducing a parallel increase in oxidative stress through STAT1-dependent mechanisms.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators designed a systemic metastasis-targeted nanotherapeutic (H@CaPP) to hinder the multiple steps of tumor metastasis. H@CaPP efficiently inhibited tumor metastasis and prolonged overall survival of 4T1 mammary tumor-bearing mice.
[Nature Communications] |
|
|
|
| Researchers generated and analyzed knock-in mice expressing a mutant form of PTEN that could not be phosphorylated by ataxia telangiectasia mutated (ATM), which accelerated tumorigenesis in a model of HER2-positive breast cancer.
[Cell Death & Differentiation] |
|
|
|
| Using mouse mammary tissue ex vivo, scientists showed that testosterone-related progestins induced the progesterone receptor (PR) target and mediator of PR signaling-induced cell proliferation receptor activator of NF-κB ligand, whereas progestins with anti-androgenic properties in reporter assays did not.
[EMBO Molecular Medicine] |
|
|
|
| Pooled fitness screens in two breast cancer cell lines revealed peptides, which selectively reduced cellular proliferation, implicating oncogenic protein domains important for cell fitness.
[Cell Systems] |
|
|
|
| Investigators established RBM39/MLL1 as a major contributor to the abnormal epigenetic landscape in breast cancer and laid the foundation for peptide-mediated cancer-specific therapy based on disruption of RBM39 epigenomic functions.
[Cell Reports] |
|
|
|
| The authors found that Lnc-408, a novel long noncoding RNA, was significantly upregulated in breast cancer (BC) cells undergoing epithelial-mesenchymal transformation and in BC tumor with lymphatic metastases compared with those without lymphatic metastases.
[Oncogene] |
|
|
|
| Researchers prepared shell-core structure nanoparticles which inhibited tumor growth and angiogenesis in vitro and in MDA-MB-231 tumor-bearing mice via downregulating the sphingosine 1 phosphate receptor 1/phosphorylated signal transducer and activator of transcription 3/vascular endothelial growth factor A (S1PR1/P-STAT3/VEGFA) axis.
[Journal of Nanobiotechnology] |
|
|
|
| Scientists investigated the expression and function of SEC61G in breast cancer, and demonstrated that knockdown of SEC61G suppressed breast cancer cell proliferation, migration, invasion, and promoted breast cancer cell apoptosis in vitro.
[Cell Death & Disease] |
|
|
|
| Investigators demonstrated that long non-coding RNA prostate androgen-regulated transcript 1 (PART1) was enriched in TNBCs. Knockdown of PART1 in TNBC cell lines and a patient-derived xenograft decreased cell proliferation, migration, tumor growth, and mammosphere formation potential.
[Cancers] |
|
|
|
| Researchers investigated the relevance of the interactions between N-Myc and STAT Interactor protein (NMI) and various STATs to normal mammary development and cancer.
[Oncogenesis] |
|
|
|
| Mesenchymal stem/stromal cells stimulated robust expression of LINC01119 in TNBC cells, which in turn induced suppression of cytokine signaling 5 (SOCS5), leading to accelerated cancer cell growth and tumorigenesis.
[npj Breast Cancer] |
|
|
|
| Investigators studied the effect of syndecan-1 siRNA depletion and hyaluronic acid treatment on hallmark processes of cancer in breast cancer cell lines of different levels of aggressiveness.
[International Journal of Molecular Sciences] |
|
|
|
|
| The authors evaluate the use of cyclin-dependent kinase 4/6 inhibitors in the adjuvant setting based on the continued high rate of relapse in patients with node-positive, hormone receptor-positive breast cancer.
[Cancer] |
|
|
|
| Recent investigations have shown the crucial effects of circrRNAs in the evolution of breast cancer. Scientists explore the results of researches that appraised the role of circRNAs in breast cancer.
[Pathology Research and Practice] |
|
|
|
|
| Novartis Pharma AG announced updated median overall survival (OS) results for Kisqali® in combination with fulvestrant in postmenopausal women with HR+/HER2– metastatic breast cancer. This combination demonstrated a clinically relevant OS benefit of more than a year compared with fulvestrant alone.
[Novartis Pharma AG] |
|
|
|
| Cannabics Pharmaceuticals, Inc. announced the launching of a new research program for the development of a breast cancer antitumor targeting medicine following the successful completion of a series of preclinical experiments.
[Cannabics Pharmaceuticals, Inc. (PR Newswire, Inc.)] |
|
|
|
|
| June 21 – 24, 2021
Virtual |
|
|
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York City, New York, United States |
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
